Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
← catalyst calendarNCT05308264 · readout ≤ 12 d
Sponsored by Rigel Pharmaceuticals (industry) · RIGL — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
86estimated
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-12 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-04-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Low Risk Myelodysplastic Syndromes
Intervention
- Drug: R906289 Monosodium (R289 Na) — also filed as R906289 Monosodium
Primary outcome
what the primary-completion date above is the date OFSafety and Tolerability
measured 2 Year
Permalink · RIGL's whole pipeline · Catalyst calendar · Every registered study · What changed